Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Vemircopan with Metformin, Rosuvastatin, OCs, and Carbamazepine
NCT06071442Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2024
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vemircopan in paroxysmal nocturnal hemoglobinuria (PNH) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Maximum observed plasma concentration at 120 hours, Area under the concentration-time curve from time zero to the last quantifiable concentration at 120 hours and 1 more. Started Jan 2024; status: completed.
02
Drugs
vemircopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06071442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06071442.